Landos Biopharma Inc Net Income per Employee (LABP), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Landos Biopharma Inc   (NASDAQ: LABP)
 

Landos Biopharma Inc Net Income per Employee

LABP's Quarterly Results, Trends, Rankings, Statistics
Landos Biopharma Inc recorded a cumulative net loss of $-25 million during 12 month ending in the first quarter 2024.
The Healthcare sector has seen employees of 13 other companies achieving higher income per employee. While Landos Biopharma Inc 's total ranking has deteriorated compared to the previous quarter from 216 to 251.


What is Income per Employee Ratio?






LABP Net Income per Employee (Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -918,444 -812,407 -779,556 -854,963 -1,127,630
LABP's Total Ranking # 251 # 216 # 0 # 0 #
Seq. Net Income Change - - - - -


LABP Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 19
Overall Market # 251

Net Income per Employee Statistics
High Average Low
$ 723,815 $ -559,275 $ -1,609,926
(Dec 31 2023)   (Mar 31 2022)







Companies with similar Income per Employee for 12 month ending Mar 31 2024, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2024Number of Employees Mar 31 2024


Date modified: 2026-08-31T01:33:40+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.